B7-33 vs Vesugen
A side-by-side research comparison of B7-33 and Vesugen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | B7-33 | Vesugen |
|---|---|---|
| Full name | B7-33 (Relaxin Peptide Analog) | Vesugen (Lys-Glu-Asp Vascular Bioregulator) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research peptide (preclinical) | Research compound (peptide bioregulator) |
| Mechanism | Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin. | As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance. |
| Molecular weight | ~3.3 kDa | ~390 Da |
| Half-life | Short (peptide) | Short (peptide) |
| Bioavailability | Injection (research) | Oral (encapsulated) or subcutaneous |
| Typical dose | Not established for humans | ~1-2 capsules/day or short injectable courses |
| Frequency | Research only | Once daily |
| Route | Injection (research) | Oral capsule or subcutaneous |
B7-33 reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
Vesugen reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Related comparisons
Research and educational reference only. Not medical advice.